The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
Subscribe To Our Newsletter & Stay Updated
